News Release

Study examines heart and kidney outcomes of adults with nephrotic syndrome

Patients face high risks of kidney failure and cardiovascular problems

Peer-Reviewed Publication

American Society of Nephrology


  • Primary nephrotic syndrome is characterized by high urinary excretion of protein, low protein in the blood, high cholesterol, and swelling in the arms and legs.
  • A new analysis highlights the high risk of kidney failure and different cardiovascular complications in patients with primary nephrotic syndrome.

Washington, DC (June 18, 2021) -- A form of kidney disease called primary nephrotic syndrome is characterized by high urinary excretion of protein, low protein in the blood, high cholesterol, and swelling in the arms and legs. Patients may face a range of negative health outcomes, but the extent of these effects are unknown. In a study appearing in an upcoming issue of JASN, investigators evaluated kidney, cardiovascular, and mortality outcomes in adults with primary nephrotic syndrome.

Alan S. Go, MD (Kaiser Permanente Northern California Division of Research) and his colleagues examined data from a large, integrated healthcare delivery system to identify adults with primary nephrotic syndrome over a 16-year period. The researchers compared 907 patients' long-term kidney and cardiovascular outcomes with those from 89,593 adults without kidney disease.

Over a median follow-up of 4.5 years, adults with primary nephrotic syndrome had a 19.63-times higher risk of developing kidney failure, a 2.58-times higher risk of acute coronary syndrome, a 3.01-times higher risk of heart failure, a 1.80-times higher risk of ischemic stroke, a 2.56-times higher risk of venous thromboembolism, and a 1.34-times higher risk of death compared with controls.

Primary nephrotic syndrome can result from diseases called minimal change disease, focal segmental glomerulosclerosis, or membranous nephropathy. In this study, focal segmental glomerulosclerosis was associated with the highest risk of kidney failure, followed by membranous nephropathy and minimal change disease, but there were no significant differences in the risks of cardiovascular complications or death by cause of primary nephrotic syndrome.

"Our study highlights the high risk of kidney failure and the underappreciated excess risks of different arterial and venous cardiovascular complications linked to primary nephrotic syndrome due to focal segmental glomerulosclerosis, membranous nephropathy, or minimal change disease. Additional information is needed on the most effective ways to lower the risks of both kidney and cardiovascular complications in patients," said Dr. Go. "Our study also points to the need for patients with primary nephrotic syndrome to be identified as early as possible so that they can begin to implement lifestyle changes--such as moving toward a healthy diet, stopping smoking, getting more exercise--and to be evaluated for preventive therapies that can reduce their risk for both cardiovascular disease and kidney failure."


Study co-authors include Thida C. Tan, MPH; Glenn M. Chertow, MD, MPH; Juan D. Ordonez, MD, MPH; Dongjie Fan, MSPH; David Law, MD; Leonid Yankulin, MD; Janet M. Wojcicki, PhD, MPH; Sijie Zheng, MD, PhD; Kenneth K. Chen, MD; Farzien Khoshniat-Rad, BS; Jingrong Yang, MA; and Rishi V. Parikh, MPH.

Disclosures: The study was supported by a research grant from the Brin Wojcicki Foundation to Dr. Go through Kaiser Permanente Northern California. Dr. Chertow's relevant disclosures include a research grant from Amgen, and fees from Ardelyx, AstraZeneca, Baxter, Cricket, DiaMedica, Gilead Sciences, Reata, Sanifit, Vertex, Satellite Healthcare, Angion, Bayer, ReCor, and other disclosures from CloudCath, Durect, and Outset. The rest of the authors reported no financial disclosures.

The article, titled "Primary Nephrotic Syndrome and Risks of End-Stage Kidney Disease, Cardiovascular Events and Death: The Kaiser Permanente Nephrotic Syndrome Study," will appear online at on June 18, 2021, doi: 10.1681/ASN.2020111583.

The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 21,000 members representing 131 countries. For more information, visit

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.